

VIACELL INC
Form 8-K
August 09, 2007

Table of Contents

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): August 9, 2007
VIACELL, INC.
(Exact name of registrant as specified in its charter)**

Delaware	000-51110	04-3244816
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)
	245 First Street, Cambridge, Massachusetts 02142 (Address of Principal Executive Offices) (Zip Code)	

Registrant's telephone number, including area code: (617) 914-3400

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

TABLE OF CONTENTS

Item 2.02. Results of Operations and Financial Condition

Item 9.01 Financial Statements and Exhibits.

SIGNATURE

EXHIBIT LIST

Press Release dated August 9, 2007

Table of Contents

Item 2.02. Results of Operations and Financial Condition

On August 9, 2007, ViaCell, Inc. issued a press release announcing its results of operations and financial condition for the second quarter of 2007.

The information furnished herewith pursuant to Item 2.02 of this Current Report shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1 Press release issued by ViaCell, Inc. dated August 9, 2007.

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VIACELL, INC.

Date: August 9, 2007

By: /s/ John F. Thero

Name: John F. Thero

Title: Senior Vice President, Finance
and Chief Financial Officer

Table of Contents

EXHIBIT LIST

Exhibit	Description
99.1	Press release issued by ViaCell, Inc. dated August 9, 2007